MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
Open accessAbstract
BACKGROUND: Overexpression of microRNA-182 (miR-182) is found in various human cancers, including non-small cell lung cancer (NSCLC). Our aim is to investigate the association of miR-182 expression with the sensitivity of NSCLC to cisplatin. METHODS: TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-182 and programmed cell death 4 (PDCD4) protein. miR-182 and (or) PDCD4 depleted cell lines were generated using miR-182 inhibitor and (or) siRNA. The viabilities of treated cells were analyzed using MTT assay. RESULTS: The expression level of miR-182 in A549 cell line was significantly higher than that in NHBE cell line (p < 0.01). Transfection of miR-182 inhibitor induced sensitivity of A549 cells to cisplatin. A549 cells transfected with PDCD4 siRNA became more resistant to cisplatin therapy. We found an increase PDCD4 protein level following the transfection of miR-182 inhibitor using Western blot analysis. In addition, the enhanced growth-inhibitory effect by miR-182 inhibitor was weakened after the addition of PDCD4 siRNA. CONCLUSIONS: The results of the present study demonstrated that overexpression of miR-182 may involve in chemoresistance of NSCLC cells to cisplatin by down-regulating PDCD4. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1793467320130186.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Besides miR21, many other microRNAs such as miR182, miR16, miR150, and miR499 target PDCD4 mRNA down-regulating PDCD4 expression in different cellular systems.
“Besides miR21, many other kinds of microRNA such as miR182, miR16, miR150, miR499 and other microRNAs has been shown to target the PDCD4 mRNA down-regulating PDCD4 expression in different cellular systems [58,59,60,61].”
From Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions (2019) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499 · see citing works
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,592 · see citing works
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · see citing works
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882 · see citing works
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · see citing works
Farazi, T. A., Spitzer, J., Morozov, P. S., & Tuschl, T. (2010) · The Journal of Pathology · doi:10.1002/path.2806 · Cited by 892 · see citing works
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Shuomin, Zhu, Hailong, H., Wu, Fangting, Daotai, Nie, Shijie, Sheng, Yin-Yuan, et al. (2008) · Cell Research · Cited by 831 · see citing works
MicroRNA regulation by RNA-binding proteins and its implications for cancer
van Kouwenhove, M., Kedde, M., & Agami, R. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3107 · Cited by 617 · see citing works
Segura, M. F., Hanniford, D., Menéndez, S., Reavie, L. B., Zou, X., Álvarez-Díaz, S., Zakrzewski, J., Blochin, E., Rose, A. E., Bogunovic, D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808263106 · Cited by 538 · see citing works
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R. A., Gottipati, P., Muschel, R. J., Beech, J. S., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 428 · see citing works
Mechanisms of apoptosis avoidance in cancer
Reed, J. C. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199901000-00014 · Cited by 371 · see citing works
miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Galluzzi, L., Morselli, E., Vitale, I., Kepp, O., Senovilla, L., Criollo, A., Servant, N., Paccard, C., Hupé, P., Robert, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3112 · Cited by 281 · see citing works
Xiong, S., Zheng, Y., Jiang, P., Liu, R., Liu, X., & Chu, Y. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.805 · Cited by 192 · see citing works
Liu, X.-H., Lu, K., Wang, K.-M., Sun, M., Zhang, E., Yang, J., Yin, D., Liu, Z., Zhou, J., Liu, Z., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-348 · Cited by 178 · see citing works
miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival
Jiang, L., Mao, P., Song, L., Wu, J., Huang, J., Lin, C., Yuan, J. X., Qu, L., Cheng, S., & Li, J. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090812 · Cited by 167 · see citing works
Guan, P., Yin, Z., Li, X., Wu, W., & Zhou, B. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-54 · Cited by 167 · see citing works
Feng, S., Cong, S., Zhang, X., Bao, X., Wang, W., Li, H., Wang, Z., Wang, G., Xu, J., Du, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr232 · Cited by 158 · see citing works
Self-citationGao, W., Lu, X. J., Liu, L., Xu, J., Feng, D., & Shu, Y. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19073 · Cited by 144 · see citing works
Wang, Y., Guo, R., Guo, R., Wei, S., & Yin, L. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24488 · Cited by 128 · see citing works
Functional analysis of microRNAs in human hepatocellular cancer stem cells
Meng, F., Glaser, S. S., Francis, H., DeMorrow, S., Han, Y., Passarini, J. D., Stokes, A., Cleary, J. P., Liu, X., Venter, J. K., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01282.x · Cited by 125 · see citing works
New Developments and Approaches in the Platinum Arena
Judson, I. R., & Kèlland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00004 · Cited by 121 · see citing works
MicroRNA-182 plays an onco-miRNA role in cervical cancer
Tang, T., Wong, H. K., Gu, W., Yu, M., To, K., Wang, C. C., Wong, Y. F., Cheung, T. H., Chung, T. K. H., & Choy, K. W. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.043 · Cited by 110 · see citing works
miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2
Qiu, T., Zhou, L. Q., Wang, T., Xu, J., Wang, J., Chen, W., Xin Min, Z. H. O. U., Huang, Z., Zhu, W., Shu, Y., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1439 · Cited by 84 · see citing works
Sp1-mediated microRNA-182 expression regulates lung cancer progression
Yang, W., Chen, P.-H., Hsu, T., Fu, T.-F., Su, W., Liaw, H., Chang, W., & Hung, J. (2014) · Oncotarget · doi:10.18632/oncotarget.1608 · Cited by 78 · see citing works
Lü, Q., Lu, S., Huang, L., Wang, T., Wan, Y., Zhou, C. X., Zhang, C., Zhang, Z., & Li, X. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-145 · Cited by 68 · see citing works
miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Shah, A. A., Leidinger, P., Blin, N., & Meese, E. U. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794182980 · Cited by 68 · see citing works
microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2
Cho, H. M., Jeon, H. S., Lee, S. Y., Jeong, K. J., Park, S.-Y., Lee, H. Y., Lee, J. U., Kim, J. H., Kwon, S. J., Choi, E. J., et al. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.284 · Cited by 60 · see citing works
Kang, J., Lee, S. Y., Lee, S., Kim, Y. J., Park, J., Kwon, S. J., Na, M. J., Lee, E. J., Jeon, H. S., & Son, J. W. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.366 · Cited by 49 · see citing works
Wang, M., Wang, Y., Zang, W., Wang, H., Chu, H., Li, P., Li, M., Zhang, G., & Zhao, G. (2013) · Tumor Biology · doi:10.1007/s13277-013-1004-8 · Cited by 41 · see citing works
Self-citationHusted, S., Søkilde, R., Rask, L., Cirera, S., Busk, P. K., Eriksen, J., & Litman, T. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200255d · Cited by 35 · see citing works
Analysis of MAT3 gene expression in NSCLC
Zheng, S., Du, Y., Chu, H., Chen, X., Li, P., Wang, Y., Ma, Y., Wang, H., Zang, W., Zhang, G., et al. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-166 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 675 · see citing works
The microRNA-183 cluster: the family that plays together stays together
Dambal, S., Shah, M., Mihelich, B. L., & Nonn, L. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv703 · Cited by 213 · see citing works
MicroRNA Therapeutics in Cancer: Current Advances and Challenges
Sayed, S. R. E., Cristante, J., Guyon, L., Denis, J., Chabre, O., & Cherradi, N. (2021) · Cancers · doi:10.3390/cancers13112680 · Cited by 211 · see citing works
Zhong, S., Golpon, H. A., Zardo, P., & Borlak, J. T. (2020) · Translational research · doi:10.1016/j.trsl.2020.11.012 · Cited by 158 · see citing works
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions
Matsuhashi, S., Manirujjaman, M., Hamajima, H., & Ozaki, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092304 · Cited by 143 · see citing works
The Network of Non-coding RNAs in Cancer Drug Resistance
Corrà, F., Agnoletto, C., Minotti, L., Baldassari, F., & Volinia, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00327 · Cited by 108 · see citing works
Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance
Ayers, D., & Vandesompele, J. (2017) · Genes · doi:10.3390/genes8030095 · Cited by 107 · see citing works
Ma, Y., Liang, A., Fan, Y., Huang, Y., Zhao, X., Sun, Y. W., & Chen, X. (2016) · Oncotarget · doi:10.18632/oncotarget.8715 · Cited by 81 · see citing works
Wang, H., Wang, L., Pan, H., Wang, Y., Shi, M., Yu, H., Wang, C., Pan, X., & Chen, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.620603 · Cited by 77 · see citing works
Doghish, A. S., Ismail, A., Elrebehy, M. A., Elbadry, A. M. M., Mahmoud, H. H., Farouk, S. M., Serea, G. A. A., Elghany, R. A. A., El-Halwany, K. K., Alsawah, A. O., et al. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154053 · Cited by 77 · see citing works
What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma?
Palmini, G., Marini, F., & Brandi, M. L. (2017) · Molecules · doi:10.3390/molecules22030417 · Cited by 70 · see citing works
Shi, L., Xu, Z., Wu, G., Chen, X., Huang, Y., Wang, Y., Jiang, W., & Ke, B. (2017) · BMC Cancer · doi:10.1186/s12885-017-3132-9 · Cited by 57 · see citing works
The Roles of microRNAs in Cancer Multidrug Resistance
Pavlíková, L., Šereš, M., Breier, A., & Sulová, Z. (2022) · Cancers · doi:10.3390/cancers14041090 · Cited by 54 · see citing works
Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role
Kannampuzha, S., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02138-y · Cited by 54 · see citing works
Spitschak, A., Meier, C., Kowtharapu, B. S., Engelmann, D., & Pützer, B. M. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0563-x · Cited by 54 · see citing works
MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer
Chen, Y., Gao, Y., Zhang, K., Li, C., Pan, Y., Chen, J., Wang, R., & Chen, L. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438548 · Cited by 53 · see citing works
MicroRNA-182 promotes pancreatic cancer cell proliferation and migration by targeting β-TrCP2
Wang, S., Ji, J., Song, J., Li, X., Han, S., Lian, W., Cao, C., Zhang, X., & Li, M. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw105 · Cited by 51 · see citing works
Self-citationMicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
Fadejeva, I., Olschewski, H., & Hrzenjak, A. (2017) · Oncotarget · doi:10.18632/oncotarget.22975 · Cited by 51 · see citing works
MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer.
Chang, H., Liu, Y., Wang, L., Wang, J., Zhao, Z., Qu, J., & Sheng-fa, W. (2018) · Europe PMC (PubMed Central) · Cited by 51 · see citing works
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1
Wu, H., Liu, Q., Cai, T., Chen, Y.-D., Liao, F., & Wang, Z. (2014) · Diagnostic Pathology · doi:10.1186/s13000-014-0173-0 · Cited by 50 · see citing works
Understanding the CREB1-miRNA feedback loop in human malignancies
Wang, Y., Chen, X., Ma, R., & Gao, P. (2016) · Tumor Biology · doi:10.1007/s13277-016-5050-x · Cited by 47 · see citing works
MicroRNA-targeted therapeutics for lung cancer treatment
Xue, J., Yang, J., Luo, M., Cho, W. C. S., & Liu, X. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1263298 · Cited by 47 · see citing works
Zhang, F., Bai, Y., Wang, X., Xiang, M., Wang, X., & Mao, Z. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150830 · Cited by 43 · see citing works
Zhang, Y., He, K., & Shi, G. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484588 · Cited by 40 · see citing works
RetractedLi, C., Luo, M., Wang, J., Niu, H., Shen, Z., & Wu, Z. (2020) · ACS Sensors · doi:10.1021/acssensors.0c00212 · Cited by 39 · see citing works
Dissecting the Roles of PDCD4 in Breast Cancer
Cai, Q., Yang, H., Li, Y., & Zhu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855807 · Cited by 37 · see citing works
MiR‐182 enhances radioresistance in non‐small cell lung cancer cells by regulating FOXO 3
Chen, G., Yu, L., Dong, H., Liu, Z., & Sun, Y. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13041 · Cited by 36 · see citing works
Yang, W., Yin, Y., Bi, L., Wang, Y., Yao, J., Xu, L., & Jiao, L. (2021) · Journal of Cancer · doi:10.7150/jca.60419 · Cited by 36 · see citing works
MiR-182 promotes glucose metabolism by upregulating hypoxia-inducible factor 1α in NSCLC cells
Wang, M., Wang, W., Wang, J., & Zhang, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.06.035 · Cited by 35 · see citing works
Yang, Q., Zhang, Z., Xu, H., & Ma, C. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3490-x · Cited by 34 · see citing works
RetractedMicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin
Konoshenko, M. Y., Lansukhay, Y., Krasilnikov, S. E., & Laktionov, P. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147594 · Cited by 34 · see citing works
The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target
Sameti, P., Tohidast, M., Amini, M., Bahojb Mahdavi, S. Z., Najafi, S., & Mokhtarzadeh, A. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02972-0 · Cited by 32 · see citing works
Luo, J., Shi, K., Yin, S.-Y., Tang, R., Chen, W., Huang, L.-Z., Gan, T., Cai, Z., & Chen, G. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1378-6 · Cited by 32 · see citing works
Gao, L., Yan, S.-B., Yang, J., Kong, J.-L., Shi, K., Ma, F., Huang, L.-Z., Luo, J., Yin, S.-Y., He, R., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-019-0648-7 · Cited by 32 · see citing works
Moutabian, H., Radi, U. K., Saleman, A. Y., Adil, M., Zabibah, R. S., Chaitanya, M., Saadh, M. J., Jawad, M. J., Hazrati, E., Bagheri, H., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154789 · Cited by 30 · see citing works
Flavonoid display ability to target microRNAs in cancer pathogenesis
Singh, S., Raza, W., Parveen, S., Meena, A., & Luqman, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114409 · Cited by 29 · see citing works
Cao, S., Lin, L., Xia, X., & Wu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.20109 · Cited by 24 · see citing works
Huang, Y., Nie, X., Li, G., Fan, D., Song, L., & Zhang, X. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4587 · Cited by 24 · see citing works
Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer
Mondal, P., & Meeran, S. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1105484 · Cited by 23 · see citing works
Wu, Y., Zhu, X., Shen, R., Huang, J., Xu, X. N., & He, S. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152603 · Cited by 23 · see citing works
Galuppini, F., Censi, S., Moro, M., Carraro, S., Sbaraglia, M., Iacobone, M., Fassan, M., Mian, C., & Pennelli, G. (2021) · Cells · doi:10.3390/cells10040955 · Cited by 22 · see citing works
MiR-182-5p Modulates Prostate Cancer Aggressive Phenotypes by Targeting EMT Associated Pathways
de Souza, M. F., Cólus, I. M. D. S., Fonseca, A. S., Antunes, V. C., Kumar, D., & Cavalli, L. R. (2022) · Biomolecules · doi:10.3390/biom12020187 · Cited by 20 · see citing works
ZHENG, Y.-Z., Wen, J., Cao, X., Yang, H., Luo, K., Liu, Q., HUANG, Q.-Y., CHEN, J.-Y., & FU, J.-H. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.511 · Cited by 20 · see citing works
MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia
Arya, D., Sachithanandan, S. P., Ross, C. R., Palakodeti, D., Li, S., & Krishna, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.471 · Cited by 20 · see citing works
Double-edged sword role of miRNA-633 and miRNA-181 in human cancers
Gupta, J., Suliman, M., Ali, R., Margiana, R., Hjazi, A. M., Alsaab, H. O., Qasim, M. T., Hussien, B. M., & Ahmed, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154701 · Cited by 19 · see citing works
Analysis of non‑alcoholic fatty liver disease microRNA expression spectra in rat liver tissues
Nie, J., Li, C., Li, J., Chen, X., & Zhong, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9268 · Cited by 19 · see citing works
Luo, J., Jin, Y. J., Li, M., & Dong, L. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12024 · Cited by 15 · see citing works
Self-citationRetractedInterplay Between Non-Coding RNAs and Programmed Cell Death Proteins
Ghafouri‐Fard, S., Hussen, B. M., Mohaqiq, M., Shoorei, H., Baniahmad, A., Taheri, M. N., & Jamali, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.808475 · Cited by 15 · see citing works
miR-182 modulates cell proliferation and invasion in prostate cancer via targeting ST6GALNAC5
Bai, L., Luo, L., Gao, W., Bu, C., & Huang, J. (2021) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2020e9695 · Cited by 15 · see citing works
A pico-HPLC-LIF system for the amplification-free determination of multiple miRNAs in cells
Zhang, W., Han, Z., Liang, Y., Zhang, Q., Dou, X., Guo, G., & Wang, X. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.12.007 · Cited by 14 · see citing works
Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation
Zhang, T., Li, W., Gu, M., Wang, Z., Zhou, S., Hao, X., Li, W., & Xu, S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s305179 · Cited by 14 · see citing works
The miR-183 Cluster: Biogenesis, Functions, and Cell Communication via Exosomes in Cancer
Li, S., Wei, M., Guo, Z., Liu, M., He, Y., Li, Y., & Ma, Z. (2023) · Cells · doi:10.3390/cells12091315 · Cited by 13 · see citing works
Programmed cell death factor 4 enhances the chemosensitivity of colorectal cancer cells to Taxol
Wang, D., Hou, Q., Zhao, L., Gao, J., Xiao, Y., & Wang, A. (2019) · Oncology Letters · doi:10.3892/ol.2019.10398 · Cited by 13 · see citing works
Yang, Y.-L., WANG, W., & Xu, L. (2018) · Neoplasma · doi:10.4149/neo_2018_170110n20 · Cited by 11 · see citing works
MicroRNAs: Key Regulators in Lung Cancer
Founini, Y. E., Chaoui, I., Dehbi, H., Mzibri, M. E., Abounader, R., & Guessous, F. (2021) · MicroRNA · doi:10.2174/2211536610666210527102522 · Cited by 11 · see citing works
Neuronal activity regulates the nuclear proteome to promote activity-dependent transcription
Herbst, W. A., Deng, W., Wohlschlegel, J. A., Achiro, J. M., & Martin, K. C. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103087 · Cited by 11 · see citing works
Chen, S., Wang, Q., Zhou, X., Zhu, J., Li, T. X., & Huang, M. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5332 · Cited by 10 · see citing works
Self-citationRole of miR-182/PDCD4 axis in aggressive behavior of prostate cancer in the African Americans
Shiina, M., Hashimoto, Y., Kulkarni, P., Dasgupta, P., Shahryari, V., Yamamura, S., Tanaka, Y., & Dahiya, R. (2021) · BMC Cancer · doi:10.1186/s12885-021-08723-6 · Cited by 10 · see citing works
miR-183/96/182 Cluster Regulates the Development of Bovine Myoblasts through Targeting FoxO1
Ru, W., Liu, K., Yang, J., Liu, J., Qi, X., Huang, B., & Chen, H. (2022) · Animals · doi:10.3390/ani12202799 · Cited by 10 · see citing works
Hu, J., Wang, Z., Jinjun, W., Jian, Y., Dai, J., Wang, X., & Xiong, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s258251 · Cited by 10 · see citing works
Pleural fluid biochemical analyses: a state-of-the-art review
Zheng, W., Porcel, J. M., Lee, G., & Hu, Z.-D. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2577984 · Cited by 8 · see citing works
Expression and regulatory effects of microRNA-182 in osteosarcoma cells: A pilot study
Bian, D., Wang, X., Huang, K., ZHAI, Q.-X., Yu, G., & WU, C.-H. (2016) · Oncology Letters · doi:10.3892/ol.2016.4375 · Cited by 8 · see citing works
Zhu, C., Jiang, X., Xiao, H., & Guan, J. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10220-9 · Cited by 7 · see citing works
Zhou, J. L., Li, H., Li, N., Li, X., Zhang, H., Song, Q., & Peng, M. (2017) · PubMed Central · Cited by 7 · see citing works
Programmed cell death 4: A novel player in the pathogenesis of polycystic ovary syndrome
Zarezadeh, R., Abbasi, K., Beilankouhi, E. A. V., Navali, N., Hakimi, P., Fattahi, A., & Farzadi, L. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3905 · Cited by 6 · see citing works
Effect of lentivirus-mediated miR-182 targeting FGF9 on hallux valgus
Zhang, W., Zhao, D., Zhao, W., Cui, Y., Li, Q., & Zhang, Z. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.50984 · Cited by 5 · see citing works
Maurya, N., Meena, A., & Luqman, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144261 · Cited by 4 · see citing works
The Pathway Analysis of Micrornas Regulated Drug-Resistant Responses in HeLa Cells
Yang, Y., Dai, C., Cai, Z., Hou, A., Cheng, D., Wu, G., Li, J., Cui, J., & Xu, D. (2016) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2016.2539365 · Cited by 4 · see citing works
Silibinin: An Inhibitor of Mir-181a Gene Expression in Sk-Br-3 Breast Cancer Cell Line
Shahinfar, P., Motamed, N., Birjandian, E., & Shabanpour, O. (2017) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.51.4.89 · Cited by 3 · see citing works
Batar, B., Serdal, E., Erdal, B., & Oğul, H. (2024) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5891 · Cited by 2 · see citing works
KIAA0101 promotes cisplatin resistance through regulating cell apoptosis in lung cancer cells
Zhang, C., Liu, Y., Zhao, J., Xu, J., Pei, B., Liu, X., & Yue, X. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.28 · Cited by 2 · see citing works
The Role of miRNAs in Cisplatin-Resistant HeLa Cells
Yang, Y., Dai, C., Cai, Z., Hou, A., Cheng, D., & Xu, D. (2015) · Lecture notes in computer science · doi:10.1007/978-3-319-19048-8_30 · Cited by 1 · see citing works
Prasad, D., & Sushma, P. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9186-7_1
Shiina, M., Hashimoto, Y., Kulkarni, P., Dasgupta, P., Shahryari, V., Yamamura, S., Tanaka, Y., & Dahiya, R. (2021) · Figshare · doi:10.6084/m9.figshare.16625602
- Authors
- Ning, F.-L., Wang, F., Li, M.-L., Yu, Z.-S., Hao, Y.-Z., & Chen, S.-S.
- Affiliations
- Binzhou Medical University (CN)
- ORCID
- Wang, Feng
- Venue
- Diagnostic Pathology
- Published
- 2014-07-10
- Volume
- 9
- Issue
- 1
- Pages
- 143-143
- ISSN
- 1746-1596 (ISSN-L)
- PMC
- PMC4108001
- OpenAlex
- W2126940189
- Cited by
- 74
- References
- 31
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 10 · 2016: 7 · 2015: 4 · 2014: 1
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Diagnostic Pathology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- microRNA-182, PDCD4, non-small cell lung cancer, cisplatin, chemoresistance, chemosensitivity, miRNA inhibitors, A549 cells, cell viability
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cisplatin, Humans, Lung Neoplasms, Blotting, Western, Gene Expression Regulation, Neoplastic, RNA-Binding Proteins, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, MicroRNAs, Cell Line, Tumor, Apoptosis Regulatory Proteins, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
